Lecanemab: the game changer in the ongoing fight to treat Alzheimer’s disease?
Section
References
- Cummings, J., Lee, G., Nahed, P., Kambar, M., Zhong, K., Fonseca, J., & Taghva, K. (2022). Alzheimer's disease drug development pipeline: 2022. Alzheimers Dement (N Y), 8(1), e12295. https://doi.org/10.1002/trc2.12295
- Dhadda, S., Kanekiyo, M., Li, D., Swanson, C. J., Irizarry, M., Berry, S., . . . Berry, D. A. (2022). Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease. Alzheimers Res Ther, 14(1), 182. https://doi.org/10.1186/s13195-022-01129-x
- Jia, L., Quan, M., Fu, Y., Zhao, T., Li, Y., Wei, C., . . . Group for the Project of Dementia Situation in, C. (2020). Dementia in China: epidemiology, clinical management, and research advances. Lancet Neurol, 19(1), 81-92. https://doi.org/10.1016/S1474-4422(19)30290-X
- Soderberg, L., Johannesson, M., Nygren, P., Laudon, H., Eriksson, F., Osswald, G., . . . Lannfelt, L. (2022). Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. Neurotherapeutics. https://doi.org/10.1007/s13311-022-01308-6
- Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., . . . Cummings, J. L. (2021). A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther, 13(1), 80. https://doi.org/10.1186/s13195-021-00813-8
- Tahami Monfared, A. A., Tafazzoli, A., Ye, W., Chavan, A., & Zhang, Q. (2022). Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling. Neurol Ther, 11(2), 863-880. https://doi.org/10.1007/s40120-022-00350-y
- Tolar, M., Abushakra, S., Hey, J. A., Porsteinsson, A., & Sabbagh, M. (2020). Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. Alzheimers Res Ther, 12(1), 95. https://doi.org/10.1186/s13195-020-00663-w
- Tucker, S., Moller, C., Tegerstedt, K., Lord, A., Laudon, H., Sjodahl, J., . . . Lannfelt, L. (2015). The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis, 43(2), 575-588. https://doi.org/10.3233/JAD-140741
- van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., . . . Iwatsubo, T. (2023). Lecanemab in Early Alzheimer's Disease. N Engl J Med, 388(1), 9-21. https://doi.org/10.1056/NEJMoa2212948
- Vaz, M., Silva, V., Monteiro, C., & Silvestre, S. (2022). Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities. Clin Interv Aging, 17, 797-810. https://doi.org/10.2147/CIA.S325026
How to Cite
“Lecanemab: The Game Changer in the Ongoing Fight to Treat Alzheimer’s Disease?”. Human Brain, vol. 2, no. 1, Apr. 2023, https://doi.org/10.37819/hb.002.001.0301.
How to Cite
“Lecanemab: The Game Changer in the Ongoing Fight to Treat Alzheimer’s Disease?”. Human Brain, vol. 2, no. 1, Apr. 2023, https://doi.org/10.37819/hb.002.001.0301.
Search Panel
Article Details
Most Read This Month
License
Copyright (c) 2023 Qi Qin, Yi Tang
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
